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Abstract
Background: We have been studying the native autoimmune response to cancer through the
isolation of human monoclonal antibodies that are cancer specific from cancer patients. To facilitate
this work we previously developed a fusion partner cell line for human lymphocytes, MFP-2, that
fuses efficiently with both human lymph node lymphocytes and peripheral blood lymphocytes. Using
this unique trioma fusion partner cell line we isolated a panel of autologous human monoclonal
antibodies, from both peripheral blood and lymph node lymphocytes, which are representative of
the native repertoire of anti-cancer specific antibodies from breast cancer patients.
Methods: The current study employs immunocytochemistry, immunohistochemistry, Western
blot analysis as well as Northern blots, Scatchard binding studies and finally SEREX analysis for
target antigen identification.
Results: By application of an expression cloning technique known as SEREX, we determined that
the target antigen for two monoclonal antibodies, 27.B1 and 27.F7, derived from lymph node B-
cells of a breast cancer patient, is the PDZ domain-containing protein known as GIPC1. This
protein is highly expressed not only in cultured human breast cancer cells, but also in primary and
metastatic tumor tissues and its overexpression appears to be cancer cell specific. Confocal
microscopy revealed cell membrane and cytoplasmic localization of the target protein, which is
consistent with previous studies of this protein.
Conclusion: We have determined that GIPC1 is a novel breast cancer-associated immunogenic
antigen that is overexpressed in breast cancer. Its role, however, in the initiation and/or
progression of breast cancer remains unclear and needs further clarification.
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Background
In patients with cancer, the body mounts an immune
response following the onset of malignant disease since
the new cells are recognized as non-self. It is composed of
both immune cells that mediate innate, non-specific
immunity, and adaptive, antigen-specific immunity [1-3].
Tumor cell proteins can elicit an immune response for var-
ious reasons; aberrant gene expression (e.g. cancer-testis
antigens) [4-10], overexpression (neu/Her2) [11,12],
aberrant processing (mucin) [13,14] and mutation events
(p53) [11,15]. Although it is evident that a natural
humoral response to cancer exists, tumor-associated anti-
gens (TAAs) are generally notoriously bad immunogens.
This is likely due to systemic tolerance to the autoantigens
and, as a result, the natural humoral immune response
against tumor antigens fails to reach high antibody titers
and is not effective [16].
During the last decade, the search for TAAs that can be tar-
geted by the immune system, and as such are "immuno-
visible", has been the focus of much research in cancer
immunology. In addition, the isolation and production of
fully human monoclonal antibodies (fhMAb) to such
antigens has also made significant advances over the past
few years [16-18]. The potential utility of these antibodies
to identify TAAs, to discriminate between neoplastic and
normal tissues and potentially act as anti-cancer therapeu-
tics has been the impetus for this work.
To identify tumor-associated antigens, one of the more
fruitful approaches has been to employ naturally occur-
ring anti-cancer antibodies that arise in cancer patients. To
this end, serological expression technology (SEREX) has
facilitated the identification of novel TAAs by screening
patients' whole sera on cDNA expression libraries that
were prepared from autologous tumors or human cancer
cell lines [19-23]. This technology has led to the creation
of a database of protein antigens that are associated with
and specific to a variety of cancers. However, the native
immune response to these antigens is not identified or
captured by this methodology. Therefore, although pro-
teins that are associated specifically with cancer can be
pinpointed, the antibodies that can effectively target these
antigens remain mostly unidentified.
To overcome this limitation we designed and imple-
mented an alternate strategy that relies on a unique trioma
fusion partner cell line, MFP-2, which we developed [24].
MFP-2 can efficiently fuse with both peripheral blood and
lymph node lymphocytes. Following fusion, surviving
hybridoma clones are stable for prolonged periods and
many produce significant quantities of human mono-
clonal antibodies. We employed this unique fusion part-
ner cell line to develop a panel of native autologous fully
human monoclonal antibodies (fhMAb) that were culled
from the natural repertoire arising in breast cancer
patients [25]. These fhMAbs reacted specifically with
breast cancer cells and malignant tissues. They are useful
not only for identification of the target antigens, but also
for immunodiagnostic procedures [26] and eventually for
immunotherapy of breast cancer, since they can be pro-
duced on an industrial scale.
We identified the protein targets of two of the anti-breast
cancer autoantibodies that we isolated, and determined
that they target the protein GIPC1. Using our fhMAbs that
target GIPC1, we studied its expression in human breast
tissue and in cultured cells. We determined that this pro-
tein is specifically up-regulated in malignant breast epi-
thelial tissue/cells and in breast cancer cell lines and is not
detected in normal breast epithelia or in live primary
fibroblast cell lines. Therefore, GIPC1 is a novel breast
cancer-associated antigen that may play a role in the initi-
ation and/or progression of breast cancer.
Methods
Cell culture
All human cancer and normal cell lines were purchased
from ATCC. Human breast cancer cell lines MCF-7 and
SK-BR-3 and primary human fibroblasts are among those
used in this study. SK-BR-3 were cultured in McCoy's 5a
medium supplemented with L-glutamine and 10% FBS.
MCF-7 was grown in MEM medium supplemented with L-
glutamine, non-essential aminoacids, 10% FBS and 0.01
mg/ml bovine insulin. Fibroblasts were cultured in
DMEM, supplemented with L-glutamine and 10% FBS.
Other normal and neoplastic cell lines were cultured
according to the conditions recommended by the ATCC.
Hybridoma clones were produced and cultured according
to previously described techniques [25].
Antibody characterization
The isotype of human Abs was determined by ELISA using
murine anti-human isotype-specific MAbs to μ-, γ-, κ- and
λ-chains (Sigma, USA) and goat anti-mouse Ig (25 μg/
mL) conjugated to peroxidase and absorbed with human
Ig.
Immunocytochemistry and immunohistochemistry
Cells were plated on ethanol pre-treated cover slips
(Fisher, USA) and placed in 6-well plates (Falcon, USA) in
culture medium. After 24 hours the cover slips with
attached cells were repeatedly washed in PBS and fixed in
ethanol. Following fixation and repeated washes, cover
slips were incubated with the primary and secondary anti-
bodies according to standard protocols, stained with pro-
pidium iodide 1 μg/ml and analyzed by confocal
fluorescent microscopy using a Zeiss Axiovert 100 TV
microscope and Zeiss software. For immunohistochemis-
try randomly selected 5 μm thick sections of paraffinBMC Cancer 2008, 8:248 http://www.biomedcentral.com/1471-2407/8/248
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embedded breast cancer tissue were used. Endogenous
peroxidase activity was blocked by incubation of slides in
3% H2O2 in methanol. Following washing, tissue slides
were blocked with 5% normal goat serum in PBS. Mono-
valent Fab fragments of goat anti-human IgM+IgG (Jack-
son Immunoresearch Laboratories, Inc.), in blocking
solution, was then applied for secondary blocking. After 3
washes in PBS, the human monoclonal antibody was
applied at an approximate concentration of 5 ug/ml. The
slides were then washed and incubated with a second
FITC conjugated antibody to human κ-light chains
(Sigma, USA) and propidium iodide at 1 μg/ml. Follow-
ing a few washes, mounting medium (Biomeda, USA) and
cover slips were applied and sections were analyzed by
standard fluorescent microscopy.
Western blotting
Cells were lysed with freshly prepared ice cold lysis buffer
[20 mM Tris-HCl, pH 7.6, 420 mM NaCl, 0.25% NP40, 2
mM phenylmethylsulfonyl fluoride, 1 ug/ml leupeptin,
250 U/ml Trasylol (aprotinin)] and stored at -80°C or
used immediately. Protein concentration was determined
with the BioRad Protein Detection Reagent (BioRad). Tis-
sue samples were mechanically homogenized on ice, spun
down at 3000 g for 30 min at 4°C and the lower (non
lipid) phase was used for further analysis.
Equal amounts of protein were separated on 10% SDS
polyacrylamide gels and either Coomassie blue or silver
stained according to established techniques [27]. Follow-
ing electrophoresis, the proteins in the gel were trans-
ferred to a nitrocellulose membrane using a variation of
the methods of Towbin [28] and Burnette [29], and fol-
lowing blocking, probed with relevant primary and HRP-
conjugated secondary antibody. Membranes were proc-
essed using an enhanced chemiluminescence kit (ECL,
Amersham), and visualized on Kodak BioMax MR-1 film.
The immunoblotting with recombinant GIPC1 protein
was carried out as previously described [26].
Binding of 125I-labeled monoclonal antibody to SK-BR-3 
cells and Scatchard analysis
Antibody 27.F7 was labeled with Na-125I (specific activity
17.4 mCi/mg) (New England Nuclear, MA, USA) using
Iodogen as previously described [30]. The resulting spe-
cific activity of 125I-27.F7 was (100 mCi/mmol). SK-BR-3
cells were grown in 24-well plates supplemented with
DMEM media with 10% FCS and used in these experi-
ments at subconfluent phase at a density of 2 × 105 cells
per well. Cell monolayers were suspended with trypsin,
cooled to 4°C by placing them on ice and washed twice
with PBS containing 1% BSA (Sigma, USA). The cells
(50,000 cells per sample) were blocked with 1% BSA-PBS
for 1 hour at 4°C followed by incubation with 125I-27.F7
(approx. 105 cpm per sample) in the presence of increas-
ing concentrations of cold unlabeled 27.F7 (ranging 0.1 –
200 ng/ml) for 1 hour at 4°C. After incubation the sam-
ples were applied to Millipore filters using Millipore 96-
well membrane plates (Millipore, USA). The wells were
broken off and counted individually in a Cobra γ-counter
(Hewlett Packard, USA). Maximum binding, Bmax, was
determined by incubating varying numbers of cells (rang-
ing from 1.25 × 104 to 32 × 105 cells) with radiolabeled
27.F7 antibody. Nonspecific binding of the tracer was
determined in the presence of an excessive amount of
unlabeled antibody (500 μg/ml) and was generally less
than 5% of maximum binding. All experimental measure-
ments of Ka and the number of antigen targets per cell
were done in triplicate. Analysis of the data was per-
formed according to previously described methods [31-
33].
Antigen identification
RNA was purified from SK-BR-3 cells according to stand-
ard protocols. Preparation of mRNA was performed by
oligo dT chromatography with a kit from Stratagene (La
Jolla, CA). A lambda phage expression library was pre-
pared in lambda ZAP (Stratagene, La Jolla, CA) and
plaque lifts were screened with human monoclonal 27.B1
and 27.F7 according to previously described methods
[21,34]. Phage plaques that were positive on the first
screened were picked and two rounds of plaque purifica-
tion was performed to ensure that they were true positives.
Positive lambda phage clones were autoexcised according
to the protocol provided by Stratagene, grown as plasmids
according to standard protocols and sequenced to identify
the cDNA inserts.
Northern blot analysis
Total cellular RNA was isolated by the Guanidinium/Phe-
nol extraction method and Northern blotting was per-
formed as previously described [35,36]. Briefly, 15 μg of
RNA is denatured and electrophoresed in a 1.2% Agarose
gel along with 3.5% formaldehyde, transferred to a nylon
membrane and hybridized sequentially with 32P-labeled
cDNA probes. The GIPC1 cDNA fragment that we isolated
using SEREX technology was used for the gene specific
probe and a cDNA fragment of the GAPDH gene was used
as an internal control to normalize expression. Following
hybridization, the filters were washed and exposed for
autoradiography.
Results
A native fully human autoantibody to breast cancer 
identifies a cancer-associated antigen that localizes to the 
cytoplasm and membrane
We previously described the construction of a unique
fusion Partner cell line, MFP-2, and its use for the immor-
talization of both human peripheral blood and lymph
node B-lymphocytes [24,25]. MFP-2 was employed forBMC Cancer 2008, 8:248 http://www.biomedcentral.com/1471-2407/8/248
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the generation of hybridoma cells from lymphocytes of
breast cancer patients that produce autologous anti-breast
cancer specific antibodies. The results of that study are
described elsewhere [25]. One of these native human
monoclonal antibodies, designated 27.B1 (IgM, k), was
chosen for further study. It demonstrated an intensely
positive reactivity with two human breast cancer cell lines,
SK-BR-3 and MCF-7 and no reaction with normal diploid
primary human fibroblasts as tested by cELISA (In cELISA
whole cells are used in place of a purified antigen as in
ELISA) [25]. Confocal microscopy with 27.B1 demon-
strated the presence of the target antigen throughout the
cytosol and in addition staining of the membrane was
especially strong (see Figure 1). Furthermore, 27.B1
stained both primary and metastatic breast cancer with a
high specificity and sensitivity [25]. These results along
with a more detailed immunocytochemical and immuno-
histochemical analysis are described elsewhere [25].
The target antigen for monoclonal antibodies 27.B1 and 
27.F7 is a 42 kDa protein
To identify the size of the 27.B1 target protein, Western
blot analysis was performed using whole cell lysates from
different cell lines and tissues. Cell lysates prepared from
human breast cancer, normal breast tissue, human pros-
tate cancer and two human fibroblast cell lines were run
on PAGE under reducing conditions and blotted with
fhMAb 27.B1. The antibody reacted with a protein band
of approximately 42 kDa molecular weight that is detect-
able primarily in breast cancer cells (see Figure 2-A). There
was no detectable immunoreactivity with the human
fibroblasts' lysates and prostate cancer cell line LnCaP
whereas only traces of immunoreactivity were detected to
prostate cancer cell lines PC3 and DU-145 (data not
shown). The protein band revealed by 27.B1 appeared as
doublet with a dominant band that migrates slower on a
gel. The doublet pattern was not the same in all 27.B1 pos-
itive cells; MCF-7 cells displayed the higher molecular
weight band in much greater abundance, whereas SK-BR-
3 showed both bands in more equivalent intensity (data
not shown). Western blot analysis of the same cell lysates
under non-reducing conditions displayed no difference in
staining pattern, indicating that accessibility of the
epitope bound by 27.B1 is disulfide bond independent
and likely conformation independent.
Interestingly, we determined that another antibody,
27.F7, which was previously identified as binding breast
cancer cells and tissue with high specificity and sensitivity
[25], identified the same 42 kDa molecular weight dou-
blet as 27.B1. Furthermore, this antibody detected the
bands in the doublet with the same variability in different
cell lines as 27.B1. To test the epitope specificity of the two
antibodies one of them, 27.F7 was radiolabeled with 125I
and competitive Western blotting was performed with
Human monoclonal 27.B1 stains the membrane and cytosol Figure 1
Human monoclonal 27.B1 stains the membrane and 
cytosol. Staining of SK-BR-3 cells and breast cancer tissue 
was performed with human monoclonal 27.B1. Staining of 
the SK-BR-3 breast cancer cell line was analyzed by confocal 
microscopy and indicates that the target antigen is present in 
the membrane and cytoplasm. Staining of human breast can-
cer tissue was analyzed by standard fluorescent microscopy.BMC Cancer 2008, 8:248 http://www.biomedcentral.com/1471-2407/8/248
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both antibodies (data not shown). Pretreatment of a SK-
BR-3 cell lysate blot with unlabeled 27.F7 inhibited bind-
ing of 125I-labeled 27.F7, whereas unlabeled 27.B1 anti-
body did not inhibit binding. This suggests that if these
two antibodies are binding the same protein they likely
bind different epitopes.
To identify the molecular target(s) for 27.B1 and 27.F7,
SEREX technology was applied as previously described
[21,25,34] to a cDNA expression library prepared from
SK-BR-3 mRNA. Expression clones staining positively
with 27.F7 and 27.B1 were selected and the cDNA
sequences were found to encode the protein known as
GIPC1, following a BLAST algorithm homology search
[37]. This protein was previously identified as being
involved in the regulation of G protein signaling [38]. The
sequence of the cloned cDNA inserts are identical to the
respective sequence reported in GenBank for GIPC1.
To confirm that the 42 kDa band demonstrated in Figure
2-A is indeed GIPC-1, we performed immunoblotting
with recombinant GIPC-1 protein (Figure 2-B). For this
purpose, 27.B1 antibody was preincubated with a bacte-
rial expressed and refolded recombinant GIPC1 protein
prior to blotting (Figure 2-B, lane 1) and compared to
non-preincubated control (Figure 2-B, lane 2). These
results demonstrate that fhMAb 27.B1 binding to the
same 42 kDa band was specifically inhibited by the
recombinant protein and this confirmed the specificity of
this antibody to the GIPC1 antigen.
Scatchard analysis
Scatchard analysis of 125I-27.F7 binding to SK-BR-3 cells
revealed a two-mode pattern of binding, which matches a
model with binders of two different avidities (see Figure
3) [31]. One type of bound ligand is represented by
approximately 20% of all 27.F7 targets and binds the anti-
body with high avidity (Ka = 4.2 × 1011 M-1). The second
type of ligand binds with a lower avidity (Ka = 3.3 × 109 M-
1) and constitutes about 80% of the total antigen mole-
cules. An estimate for the total number of antigen mole-
cules per cell is approximately 3 × 105  target GIPC1
molecules per cell. The identification of two binding avid-
ities may be related to the fact that human monoclonal
antibody 27.F7 (and 27.B1) identifies a two band doublet
on a Western blot (see Figure 2). This suggests that one of
the bands may be a ligand of higher avidity while the sec-
ond one is of lower avidity. The doublet itself has been
previously reported although the reason for two bands
Scatchard analysis of human anti-GIPC1 monoclonal antibody  on antibody on SK-BR-3 cells Figure 3
Scatchard analysis of human anti-GIPC1 monoclonal 
antibody on antibody on SK-BR-3 cells. Scatchard analy-
sis of human monoclonal antibody 27.F7 performed on SK-
BR-3 cells revealed the presence of an antigen target with 
two affinities. This suggests that two populations of GIPC1 
molecules exist in these cells and may be related to the pro-
tein doublet identified by Western blot analysis in Figure 2.
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The target antigen for human monoclonal 27.B1 is a GIPC1  protein Figure 2
The target antigen for human monoclonal 27.B1 is a 
GIPC1 protein. A. The target antigen for monoclonal 27.B1 
in SK-BR-3 cells, breast cancer tissue and normal breast tis-
sue was identified by Western blot and is displayed. Human 
Ig H and L chains are present in the tissue and are recognized 
by the secondary anti-human antiserum. The target antigen is 
detected as a doublet in both the breast cancer tissue and 
SK-BR-3 cell line but is not detected in normal breast tissue. 
Both bands in the doublet are present in all breast cancer cell 
lines analyzed by Western blot but their intensity is variable. 
B. Immunoblotting with 27.B1 antibody of total cell lysates 
prepared from SK-BR-3 cells. 27.B1 antibody was preincu-
bated with recombinant GIPC1 protein prior to blotting 
(lane 1), and compared to non-preincubated control (lane 2).BMC Cancer 2008, 8:248 http://www.biomedcentral.com/1471-2407/8/248
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has not been determined [38]. It might be explained by an
alternative start codon or posttranslational modification.
GIPC1 is up-regulated in breast cancer cell lines
The strong staining by the human anti-GIPC1 mono-
clonal antibodies, 27.B1 and 27.F7, on breast cancer cell
lines and absent staining of normal cells [25] suggests that
the protein might be up-regulated. To semi-quantitatively
examine gene expression we performed Northern blot
analysis to determine if a higher level of GIPC1 specific
mRNA was indeed present in the breast cancer cell lines
relative to normal cell lines. RNA from a variety of breast
cancer cell lines along with non-neoplastic cell lines was
blotted and GAPDH expression was monitored as an
internal control to normalize expression. The results are
depicted in Figure 4. They indicate that breast cancer cells
indeed have increased expression of GIPC1 specific RNA
relative to that of normal cell lines.
Discussion and conclusion
Our studies have determined that GIPC1 is a novel breast
cancer associated antigen that is up-regulated in breast
cancer cell lines and in malignant tissue from all breast
cancer patients tested in this study. In our previous studies
[25], we determined that the reactivity of the human
monoclonal antibodies 27.B1 and 27.F7 are specific to
breast cancer tissue and cells. Our present study demon-
strated that these antibodies identify the unique antigen
target GIPC1 (GAIP interacting protein, C domain), a
PDZ domain containing protein [38,39].
GIPC1 was first described as a PDZ domain protein that
binds to the C terminus of RGS-GAIP (for regulators of G
signaling – Gαi3 interacting protein) [38]. GAIP itself is
considered to be a Gαi3 regulator, which acts as GTP-ase
activating protein switching Gαi3 into an inactive mode
[40-45]. Although the functional pathway of Gαi3  is
apparently vesicular trafficking, with GAIP serving as its
regulator, the physiological relevance of the interaction
between GIPC1 and GAIP is been actively investigated
[46-53].
With respect to breast tissue, the recognition by 27.B1 and
27.F7 of GIPC1 is strictly limited to neoplastic cells. Fur-
thermore, the subcellular localization of the bound anti-
bodies in the cell membrane and cytoplasm is consistent
with what has been previously described for GIPC1 local-
ization [46]. Taken together, our findings suggest that the
up-regulation of GIPC1 is cancer cell specific. Although
27.B1 does not detect any protein by FACS or Western
blot analysis in normal cells and tissues it is likely below
the level of detection since GIPC1 is likely involved in
many diverse cellular processes [47,49-55].
GIPC1 plays a role in mediating the assemblage of mole-
cules involved in signaling transduction pathways [53]. As
such, these molecules are involved in protein-protein
interactions and likely modulate the activity of their tar-
gets [53]. Proteins containing PDZ domains, and the
interactions that they mediate, may be involved in a wide
variety of signal transduction cascades including interac-
tion with receptors, adhesion molecules, ion channels,
gap junctions, cytoskeleton proteins and other vital pro-
teins, such as Fas [48-54,56]. Moreover, GIPC1 appears to
be a highly conserved protein. In rodents it regulates dis-
tribution of M-Sem-F, a neuronal membrane-associated
protein and binds to a glucose transporter protein, GLUT1
[57,58]. It is tempting to speculate on the role of over-
expressed GIPC1 in binding to a glucose transporter pro-
tein with the subsequent influx of glucose supporting
growth of tumor cells. Of course, other proteins may be
GIPC1 RNA expression analysis in normal and neoplastic cell  lines Figure 4
GIPC1 RNA expression analysis in normal and neo-
plastic cell lines. Panel A: Northern blot analysis of total 
RNA was performed with RNA samples from a human 
microvascular endothelial cell line (HMEC), normal breast 
epithelium cell line HBL100 and breast cancer cell lines MCF-
7, T47D, SK-BR-3, MDA231, MDA157 and MDA453. A 
probe for the GAPDH gene was used to normalize expres-
sion. Panel B: Densitometry analysis of the Northern blot 
was performed to quantitate the mRNA expression. The 
data indicates that the GIPC1 gene is upregulated in breast 
cancer cell lines.BMC Cancer 2008, 8:248 http://www.biomedcentral.com/1471-2407/8/248
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linked to GIPC1 function in cancer cells; this is currently
under investigation in our laboratory.
Research of cancer-associated antigens is an extremely
important pursuit. Identification of these antigens can
provide insight into the cause of a malignancy, identify
targets for immunotherapy and immunodiagnostics [26]
as well as lead to the development of new cancer vaccines.
Previous studies on natural monoclonal autoantibodies
from cancer patients did not describe the target antigens
[59,60]. Our studies demonstrate that by combining the
"immunoprospecting" of cancer autoantibodies and
SEREX technology discovery of target antigens for mono-
clonal cancer autoantibodies can be accomplished. In
conclusion, our studies revealed that GIPC1 is a novel
cancer-associated antigen; its role in carcinogenesis, how-
ever, needs further clarification. It also needs to be clari-
fied whether GIPC1 is a specific breast cancer-associated
antigen or it is overexpressed in other malignant diseases
as well.
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